AG
ZNTL icon

Artal Group’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Artal Group’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-87,400
Closed -$2.86M – 157
2020
Q3 		$2.86M Sell
87,400
-4,600
-5% -$161K 0.07% 116
2020
Q2 		$4.42M Buy
+92,000
New +$3.53M 0.12% 110

Other funds holding ZNTL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Artal Group's ZNTL Position: Q4 2020 in Review

Artal Group sold out of Zentalis Pharmaceuticals (ZNTL) in Q4 2020, closing a stake of 87,400 shares — an estimated $2.86M sold.

Artal Group first reported a position in ZNTL in Q2 2020 and held it in 2 quarters. The position peaked at $4.42M in Q2 2020. 107 funds tracked by Wall St. Rank hold ZNTL as of Q4 2020.

  • Artal Group reported no remaining Zentalis Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Artal Group sold 87,400 Zentalis Pharmaceuticals shares in Q4 2020, an estimated $2.86M.
  • Artal Group first reported a position in Zentalis Pharmaceuticals in Q2 2020 and held it in 2 quarters.
  • Artal Group's Zentalis Pharmaceuticals position peaked at $4.42M in Q2 2020.
  • 107 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q4 2020.

Based on Artal Group's 13F filing for Q4 2020, filed 11 Feb 2021.